Immix Biopharma director granted RSUs and stock options

Immix Biopharma director Jane Buchan reported equity compensation awards.

Rhea-AI Filing Summary

Immix Biopharma director Jane Buchan reported equity compensation awards. She received 6,250 restricted stock units of common stock, bringing her direct common stock holdings to 28,705 shares after the grant.

She was also granted options to buy 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036. The RSUs vest in full on the earlier of one year from grant or the 2027 annual meeting, while the options vest in substantially equal monthly installments over 12 months, with any remaining portion vesting at the 2027 annual meeting, in each case subject to continued service.

Insider Trade Summary

Grant/Award: 18,750 shares

Grant/Award 2 txns

Insider BUCHAN JANE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	12,500	$0.00	$0.00
Grant/Award	Common Stock	6,250	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 12,500 contracts (Direct); Common Stock — 28,705 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
2. F2. The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

Key Figures

RSU grant: 6,250 RSUs Common shares held: 28,705 shares Stock options granted: 12,500 options +2 more

5 metrics

RSU grant 6,250 RSUs Restricted stock units granted on May 22, 2026

Common shares held 28,705 shares Direct common stock holdings after RSU grant

Stock options granted 12,500 options Options on common stock granted on May 22, 2026

Option exercise price $8.78 per share Conversion or exercise price for stock options

Option expiration May 22, 2036 Expiration date of stock option grant

Key Terms

restricted stock units, 2021 Equity Incentive Plan, stock option, vest, +1 more

5 terms

restricted stock units financial

"The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2021 Equity Incentive Plan financial

"granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan"

stock option financial

"The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vest financial

"RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immix Biopharma (IMMX) director Jane Buchan receive in this Form 4 filing?

Jane Buchan received equity compensation consisting of 6,250 restricted stock units and stock options for 12,500 shares of Immix Biopharma common stock. These awards increase her equity stake and align her incentives with shareholders through time-based vesting tied to continued service.

How many Immix Biopharma (IMMX) shares does Jane Buchan own after these grants?

After the restricted stock unit grant, Jane Buchan directly holds 28,705 shares of Immix Biopharma common stock. This figure reflects her updated share position disclosed in the filing and does not include additional shares that could be acquired through stock option exercises in the future.

What are the key terms of Jane Buchan’s Immix Biopharma (IMMX) stock option grant?

Jane Buchan received options to purchase 12,500 shares of Immix Biopharma common stock at an exercise price of $8.78 per share. The options expire on May 22, 2036 and vest in substantially equal monthly installments over 12 months, subject to continued board service.

How do Jane Buchan’s Immix Biopharma (IMMX) RSUs vest?

Her 6,250 restricted stock units vest in full on the earlier of the one-year anniversary of the grant date or the date of Immix Biopharma’s 2027 annual meeting of stockholders. Vesting requires her continued service with the company through the applicable vesting date.

Are Jane Buchan’s Immix Biopharma (IMMX) equity awards tied to the 2027 annual meeting?

Yes. The RSUs vest on the earlier of one year from grant or the 2027 annual meeting, and any unvested stock options vest if the 2027 annual meeting occurs before the first anniversary. Both awards remain subject to her continued service on the board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUCHAN JANE

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CALIFORNIA 90064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		A		6,250(1)	A	$0	28,705	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.78	05/22/2026		A		12,500		(2)	05/22/2036	Common Stock	12,500	$0	12,500	D

Explanation of Responses:

1. The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.

2. The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

	/s/ Ilya Rachman as Attorney-In-Fact for Jane Buchan	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)